Individual dopaminergic neurons show raised iron levels in Parkinson disease

Neurology

Volumn 68, Issue 21, 2007, Pages 1820-1825

  Oakley, A E ^a   Collingwood, J F ^c   Dobson, J ^c   Love, G ^d   Perrott, H R ^d   Edwardson, J A ^a   Elstner, M ^b,e   Morris, C M ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF BATH   (United Kingdom)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; METAL;

ARTICLE; AUTOPSY; BIOACCUMULATION; CELL DENSITY; CELL LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ELECTRON PROBE MICROANALYSIS; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; IRON METABOLISM; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SPECTRAL SENSITIVITY; SUBSTANTIA NIGRA; X RAY MICROANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CELL COUNT; DOPAMINE; ELECTRON PROBE MICROANALYSIS; FERRITINS; HUMANS; IRON; IRON METABOLISM DISORDERS; MIDDLE AGED; NEUROGLIA; NEURONS; NEUROPIL; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SPECTRUM ANALYSIS; SUBSTANTIA NIGRA; UP-REGULATION;

EID: 34249034604     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000262033.01945.9a     Document Type: Article

References (37)

1. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
2. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
3. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
4. Abbas N, Lucking CB, Ricard S, et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum Mol Genet 1999;8:567-574.
5. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
6. Li JY, Henning Jensen P, Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience 2002;113:463-478.
7. Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2004;1012:193-208.
8. Morris CM, Candy JM, Bloxham CA, Edwardson JA. Brain transferrin receptors and the distribution of cytochrome oxidase. Biochem Soc Trans 1990;18:647-648.
9. Youdim MB, Ashkenazi R, Ben-Shachar D, Yehuda S. Modulation of dopamine receptor in the striatum by iron: behavioral and biochemical correlates. Adv Neurol 1984;40:159-170.
10. Antonini A, Leenders KL, Meier D, et al. T2 relaxation time in patients with Parkinson's disease. Neurology 1993;43:697-700.
11. Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 1994;3:277-282.
12. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 1992;59:1168-1171.
13. Spatz. Uber den Eissenachweiss in Gehirn besonders in Zentren des extrapyramidalen-motorischen Systems. 1922;77:261-390.
14. Morris CM, Candy JM, Oakley AE, et al. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) 1992;144:235-257.
15. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
16. Gnanalingham KK, Milkowski NA, Smith LA, et al. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Eur J Pharmacol 1995;277:235-241.
17. Song DD, Haber SN. Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting. J Neurosci 2000;20:5102-5114.
18. Hallgren B, Sourander P. The effect of age on the nonhaemin iron in the human brain. J Neurochem 1958;3:41-51.
19. Connor JR, Boeshore KL, Benkovic SA, Menzies SL. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 1994;37:461-465.
20. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006;38:515-517.
21. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet 2005;6:389-402.
22. Collingwood JF, Mikhaylova A, Davidson M, et al. In situ characterization and mapping of iron compounds in Alzheimer's disease tissue. J Alzheimers Dis 2005;7:267-272.
23. Mikhailova A, Davidson M, Channel JET, Guyodo Y, Batich C, Dobson J. Detection, identification and mapping of iron anomalies in brain tissue using x-ray absorption spectroscopy. J Roy Soc Interface 2005;2:33-37.
24. Gerlach M, Double K, Riederer P, et al. Iron in the Parkinsonian substantia nigra. Mov Disord 1997;12:258-260.
25. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adultonset basal ganglia disease. Nat Genet 2001;28:350-354.
26. Sofic E, Paulus W, Jellinger K, et al. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
27. Griffiths PD, Dobson BR, Jones GR, Clarke DT. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryoelectron microscopy. Brain 122:667-673.
28. Galazka-Friedman J, Bauminger ER, Koziorowski D, Friedman A. Mossbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra. Biochim Biophys Acta 2004;1688:130-136.
29. Meyron-Holtz EG, Ghosh MC, Iwai K, et al. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. Embo J 2004;23:386-395.
30. LaVaute T, Smith S, Cooperman S, et al. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet 2001;27:209-214.
31. Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry 1998;3:493-499.
32. Ostrerova-Golts N, Petrucelli L, Hardy J, et al. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-6054.
33. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001;276:44284-44296.
34. Turnbull S, Tabner BJ, El-Agnaf OM, et al. Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 2001;30:1163-1170.
35. el-Agnaf OM, Irvine GB. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans 2002;30:559-565.
36. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
37. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40.